Immune checkpoint inhibitors (ICIs), a major type of cancer immunotherapy, don't do much for hospitalized cancer patients, ...

"Without careful consideration of the impact of these changes, we risk long-term damage" to medical research, writes Dr. .

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

Amos Cancer Center for treatment in November 2023. Transitioning into chemotherapy after her cancer diagnosis was difficult. I ...